Combination Study of SV-BR-1-GM With Retifanlimab
← catalyst calendarSponsored by BriaCell Therapeutics Corporation (industry) · BCTX — their whole pipeline →. With LumaBridge.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
36actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-03-16 | actual | When the study began enrolling |
| Primary completion | 2026-03-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-24 | actual | The whole study's end, after follow-up |
| First posted | 2017-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Breast Neoplasm
- Metastatic Breast Cancer
- Breast Cancer Metastatic
Interventions
- Biological: SV-BR-1-GM
- Drug: Low dose cyclophosphamide — also filed as Cytoxan
- Drug: Interferon Inoculation
- Drug: retifanlimab — also filed as INCMGA00012
Primary outcomes
what the primary-completion date above is the date OFEvaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]
measured Through study completion, an average of 1 year
Evaluate the Proportion of Patients with Abnormalities in Safety Laboratory Parameters that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]
measured Through study completion, an average of 1 year
Evaluate changes in the electrocardiogram QT interval that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab)[Safety]
measured Through study completion, an average of 1 year
Permalink · BCTX's whole pipeline · Catalyst calendar · Every registered study · What changed